Immuneering (IMRX) Accumulated Expenses (2020 - 2026)
Immuneering (IMRX) posted quarterly Accumulated Expenses of $3.1 million for Q1 2026, down 9.58% year-over-year from $3.4 million in Q1 2025, and down 60.93% quarter-over-quarter from $7.8 million in Q4 2025.
Immuneering (IMRX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Immuneering's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 9.58% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 9.58% YoY), while the FY2025 annual figure was $7.8 million, up 57.69% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $3.1 million, down from $7.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $7.8 million in Q4 2025, with the low at $1.7 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $3.4 million (2025), against an average of $3.9 million.
- Peak annual rise in Accumulated Expenses reached 20095.41% in 2022, while the deepest fall reached 32.91% in 2022.
- Immuneering's Accumulated Expenses stood at $4.5 million in 2022, then climbed by 14.95% to $5.2 million in 2023, then slipped by 3.88% to $5.0 million in 2024, then soared by 57.69% to $7.8 million in 2025, then tumbled by 60.93% to $3.1 million in 2026.
- Business Quant data shows IMRX's Accumulated Expenses at $3.1 million in Q1 2026, $7.8 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.09 Mn |
| Mar 31, 2026 | 3.06 Mn |
| Dec 31, 2025 | 7.84 Mn |
| Sep 30, 2025 | 7.48 Mn |
| Jun 30, 2025 | 4.51 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 5.17 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 2.43 Mn |
| Mar 31, 2023 | 2.41 Mn |
| Dec 31, 2022 | 4.50 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | 2.23 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 211,772.00 |
| Sep 30, 2021 | 11,064.00 |